Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 …
T Akizawa, M Ueno, T Shiga… - … Apheresis and Dialysis, 2020 - Wiley Online Library
Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …
anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis …
Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open‐label study
T Akizawa, T Otsuka, M Reusch… - … Apheresis and Dialysis, 2020 - Wiley Online Library
Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat
anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24 …
anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24 …
A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis …
T Akizawa, Y Yamaguchi, T Otsuka, M Reusch - Nephron, 2020 - karger.com
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …
Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active …
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …
[HTML][HTML] Phase 3 study of roxadustat to treat anemia in non–dialysis-dependant CKD
T Akizawa, M Iwasaki, T Otsuka, Y Yamaguchi… - Kidney international …, 2021 - Elsevier
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated safety and efficacy versus placebo in phase III trials in patients with …
has demonstrated safety and efficacy versus placebo in phase III trials in patients with …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
T Akizawa, Y Yamaguchi, Y Majikawa… - Therapeutic …, 2021 - Wiley Online Library
Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment
of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat …
of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat …
Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in Therapy, 2019 - Springer
Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney …
A Besarab, R Provenzano, J Hertel… - Nephrology Dialysis …, 2015 - academic.oup.com
Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients
T Akizawa, K Tanaka-Amino, T Otsuka… - American Journal of …, 2021 - karger.com
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for
treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese …
treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese …